INT36642

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1988
Last Reported 2007
Negated 0
Speculated 0
Reported most in Abstract
Documents 4
Total Number 4
Disease Relevance 0.89
Pain Relevance 2.15

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Pde1a) cytoplasm (Pde1a)
Anatomy Link Frequency
nerve 1
neurons 1
Pde1a (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Restless leg syndrome 9 100.00 Very High Very High Very High
Glutamate 8 98.72 Very High Very High Very High
adenocard 15 97.40 Very High Very High Very High
cocaine 1 94.08 High High
Clonidine 1 93.72 High High
agonist 1 93.44 High High
Neuronal excitability 2 86.24 High High
Spinal cord 7 86.04 High High
nMDA receptor antagonist 1 84.96 Quite High
noradrenaline 2 83.12 Quite High
Disease Link Frequency Relevance Heat
Increased Venous Pressure Under Development 10 100.00 Very High Very High Very High
Peripheral Arterial Disease 1 92.28 High High
Nociception 2 71.04 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Facilitation could have been due to inhibition of a calmodulin-dependent enzyme which could not be identified from the present results.
Negative_regulation (inhibition) of calmodulin-dependent
1) Confidence 0.43 Published 1988 Journal Eur. J. Pharmacol. Section Abstract Doc Link 3378568 Disease Relevance 0 Pain Relevance 0.22
Thus, our data suggest that zaprinast-evoked adenosine accumulation is likely to be mediated by stimulation of glutamate release by a cAMP- and PKA-dependent mechanism, most likely by inhibition of PDE1 in neurons.
Negative_regulation (inhibition) of PDE1 in neurons associated with glutamate and adenocard
2) Confidence 0.08 Published 2004 Journal Eur. J. Neurosci. Section Abstract Doc Link 15147301 Disease Relevance 0 Pain Relevance 0.80
We studied 8-methoxy-IBMX as a selective PDE1 inhibitor, erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) and BAY 60-7550 as selective PDE2 inhibitors, sildenafil as a selective PDE5 inhibitor, dipyridamole as a mixed type PDE5 and PDE10 inhibitor, rolipram as a PDE4 inhibitor, and SCH 81566 as a selective PDE9 inhibitor. cGMP-IR structures (nerve fibers, axons, and terminals) were characterized using the following neurochemical markers: vesicular transporter molecules for acetylcholine, GABA, and glutamate (type 1 and type 2), parvalbumin, glutamate transporter molecule EAAT3, synaptophysin, substance P, calcitonin gene-related peptide, and isolectin B4.
Negative_regulation (inhibitor) of PDE1 in nerve associated with glutamate, gaba, calcitonin gene-related peptide and substance p
3) Confidence 0.03 Published 2006 Journal J. Chem. Neuroanat. Section Abstract Doc Link 16621445 Disease Relevance 0.07 Pain Relevance 0.35
NT-702 selectively inhibited PDE3 (IC(50)=0.179 and 0.260 nM for PDE3A and 3B) more potently than cilostazol (IC(50)=231 and 237 nM for PDE3A and 3B) among recombinant human PDE1 to PDE6.
Negative_regulation (inhibited) of PDE1 associated with restless leg syndrome
4) Confidence 0.01 Published 2007 Journal Life Sci. Section Abstract Doc Link 17850826 Disease Relevance 0.82 Pain Relevance 0.78

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox